정맥혈전증의 최신 치료: 항응고치료를 중심으로

키워드

참고문헌 (28)

1. Jang MJ, "Incidence of venous thromboembolism in Korea : from the Health Insurance Review and Assessment Service database", J Thromb Haemost, 9, pp.85~91 (2011)
2. Kearon C, "Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2), pp.419~494 (2012)
3. Agnelli G, "Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis : Warfarin Optimal Duration Italian Trial Investigators", N Engl J Med, 345, pp.165~169 (2001)
4. Boutitie F, "Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials", BMJ, 342, pp.3036~ (2011)
5. Schulman S, "The duration of oral anticoagulant therapy after a second episode of venous thromboembolism : the Duration of Anticoagulation Trial Study Group", N Engl J Med, 336, pp.393~398 (1997)
6. Garcia DA, "American College of Chest Physicians. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2), pp.24~43 (2012)
7. Schulman S, "Advances in the management of venous thromboembolism", Best Pract Res Clin Haematol, 25, pp.361~377 (2012)
8. Goudable C, "Pharmacokinetics of a low molecular weight heparin(Fraxiparine)in various stages of chronic renal failure", Nephron, 59, pp.543~545 (1991)
9. Becker RC, "Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes", Am Heart J, 143, pp.753~759 (2002)
10. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX, "Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment", Thromb Res, 105, pp.225~231 (2002)
11. Lim W, "Meta-analysis : low-molecular-weight heparin and bleeding in patients with severe renal insufficiency", Ann Intern Med, 144, pp.673~684 (2006)
12. Büller HR, "Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism", N Engl J Med, 349, pp.1695~1702 (2003)
13. Büller HR, "Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis : a randomized trial", Ann Intern Med, 140, pp.867~873 (2004)
14. Rosendaal FR, "A method to determine the optimal intensity of oral anticoagulant therapy", Thromb Haemost, 69, pp.236~239 (1993)
15. Veeger NJ, "Individual time within target range in patients treated with vitamin K antagonists : main determinant of quality of anticoagulation and predictor of clinical outcome : a retrospective study of 2300 consecutive patients with venous thromboembolism", Br J Haematol, 128, pp.513~519 (2005)
16. Van Walraven C, "Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model", J Clin Epidemiol, 62, pp.1306~1315 (2009)
17. Holbrook A, "Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2), pp.152~184 (2012)
18. Kim YK, "Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range : a pilot study", J Thromb Haemost, 8, pp.101~106 (2010)
19. Nieuwlaat R, "Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy", Thromb Haemost, 108, pp.1228~1235 (2012)
20. Adam SS, "Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism : a systematic review", Ann Intern Med, 157, pp.796~807 (2012)
21. Weitz JI, "American College of Chest Physicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2), pp.120~151 (2012)
22. Schulman S, "Dabigatran versus warfarin in the treatment of acute venous thromboembolism", N Engl J Med, 361, pp.2342~2352 (2009)
23. Bauersachs R, "Oral rivaroxaban for symptomatic venous thromboembolism", N Engl J Med, 363, pp.2499~2510 (2010)
24. Büller HR, "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism", N Engl J Med, 366, pp.1287~1297 (2012)
25. Agnelli G, "Apixaban for extended treatment of venous thromboembolism", N Engl J Med, 368, pp.699~708 (2013)
26. Schulman S, "or placebo in venous thromboembolism", N Engl J Med, 368, pp.709~718 (2013)
27. Schulman S, "How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch", Blood, 119, pp.3016~3023 (2012)
28. Peacock WF, "Emergency management of bleeding associated with old and new oral anticoagulants", Clin Cardiol, 35, pp.730~737 (2012)

관련 논문AI추천